Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data https://ift.tt/uBaz92P

In a late stage trial Dupixent led to a 30 per cent reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD). A Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and COPD respiratory symptoms.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/eJIP5mW